Bone Marrow Mononuclear Cells Transplantation in Treatment of Established Bronchopulmonary Dysplasia: A Case Report

Nguyen Thanh Liem, Tran Lien Anh, Trieu T Hong Thai, Bui Viet Anh, Nguyen Thanh Liem, Tran Lien Anh, Trieu T Hong Thai, Bui Viet Anh

Abstract

BACKGROUND Bronchopulmonary dysplasia (BDP) is an incurable disease. This study reports the successful treatment of a 30-week-old neonate with established bronchopulmonary dysplasia by bone marrow mononuclear cells (BM MNCs) transplantation. CASE REPORT The preterm infant with BPD requiring continuous oxygen administration for 4 months post-delivery underwent BM MNCs. Bone marrow was obtained from the patient's iliac crests and mononuclear cells were isolated by density gradient centrifugation method. BM MNCs were delivered via endotracheal and intravenous routes. After BM MNCs transplantation, remarkable improvements were observed in oxygen saturation and lung CT as the infant was gradually weaned off oxygen supply. CONCLUSIONS BM MNCs transplantation offers promising treatment of BPD.

Conflict of interest statement

Conflict of interest: None declared

Conflict of interests

None.

Figures

Figure 1.
Figure 1.
Chest X-ray at 35 days after delivery.
Figure 2.
Figure 2.
Chest X-ray after 3 cycles of treatment with Dexamethasone.
Figure 3.
Figure 3.
Chest CT before mononuclear cells transplantation.
Figure 4.
Figure 4.
Chest CT after mononuclear cells transplantation.

References

    1. Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA. 2015;314(10):1039–51.
    1. Northway WH, Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357–68.
    1. Jain D, Bancalari E. Bronchopulmonary dysplasia: Clinical perspective. Birth Defects Res A Clin Mol Teratol. 2014;100(3):134–44.
    1. Bhandari A, McGrath-Morrow S. Long-term pulmonary outcomes of patients with bronchopulmonary dysplasia. Semin Perinatol. 2013;37(2):132–37.
    1. Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009;180(11):1122–30.
    1. Van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009;180(11):1131–42.
    1. Zhang H, Fang J, Su H, et al. Bone marrow mesenchymal stem cells attenuate lung inflammation of hyperoxic newborn rats. Pediatr Transplant. 2012;16(6):589–98.
    1. Zhang X, Wang H, Shi Y, et al. Role of bone marrow-derived mesenchymal stem cells in the prevention of hyperoxia-induced lung injury in newborn mice. Cell Biol Int. 2012;36(6):589–94.
    1. Chang YS, Oh W, Choi SJ, et al. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant. 2009;18(8):869–86.
    1. Sung DK, Chang YS, Ahn SY, et al. Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: Gene expression profiles and histopathology. PLoS One. 2015;10(8):e0135574.
    1. Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. 2014;164(5):966–72.
    1. Ahn SY, Chang YS, Kim JH, et al. Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr. 2017;185:49–54. e2.
    1. Nguyen LT, Nguyen AT, Vu CD, et al. Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: An open label uncontrolled clinical trial. BMC Pediatrics. 2017;17(1):104.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe